• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of postmedjPostgraduate Medical JournalCurrent TOCInstructions for authors
Postgrad Med J. Sep 1995; 71(839): 513–524.
PMCID: PMC2398230

Renal dysfunction associated with liver transplantation.

Abstract

It has been known for some time that a variety of liver diseases affect kidney function, but renal dysfunction associated with orthotopic liver transplantation has received scant attention. Although the mechanisms mediating these abnormalities are incompletely defined, advances in the understanding of renal pathophysiology after liver transplantation have made it possible to develop new treatment strategies. Aggressive and early intervention to diagnose and treat renal complications associated with liver transplantation should be the goal for transplant centres.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation (1). N Engl J Med. 1989 Oct 12;321(15):1014–1022. [PMC free article] [PubMed]
  • Otte JB, de Ville de Goyet J, Alberti D, Balladur P, de Hemptinne B. The concept and technique of the split liver in clinical transplantation. Surgery. 1990 Jun;107(6):605–612. [PubMed]
  • Gentilini P, Laffi G, Buzzelli G, Stefani P, Scarpelli P, Paladini S, Smorlesi C, La Villa G, Forti G. Functional renal alterations in chronic liver diseases. Digestion. 1980;20(2):73–78. [PubMed]
  • PAPPER S, ROSENBAUM JD. Abnormalities in the excretion of water and sodium in compensated cirrhosis of the liver. J Lab Clin Med. 1952 Oct;40(4):523–530. [PubMed]
  • McCauley J, Van Thiel DH, Starzl TE, Puschett JB. Acute and chronic renal failure in liver transplantation. Nephron. 1990;55(2):121–128. [PMC free article] [PubMed]
  • Tygstrup N, Ranek L. Assessment of prognosis in fulminant hepatic failure. Semin Liver Dis. 1986 May;6(2):129–137. [PubMed]
  • Newell GC. Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis. 1987 Mar;9(3):183–190. [PubMed]
  • Morris PJ. Cyclosporine, FK-506 and other drugs in organ transplantation. Curr Opin Immunol. 1991 Oct;3(5):748–751. [PubMed]
  • Wagner K, Henkel M, Heinemeyer G, Neumayer HH. Interaction of calcium blockers and cyclosporine. Transplant Proc. 1988 Apr;20(2 Suppl 2):561–568. [PubMed]
  • SHERLOCK S, SHALDON S. The aetiology and management of ascites in patients with hepatic cirrhosis: a review. Gut. 1963 Jun;4:95–105. [PMC free article] [PubMed]
  • Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodés J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988 Sep-Oct;8(5):1151–1157. [PubMed]
  • Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis. 1986 Nov;6(4):287–298. [PubMed]
  • Schrier RW, Niederberger M, Weigert A, Ginès P. Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis. Semin Liver Dis. 1994 Feb;14(1):14–22. [PubMed]
  • Wong F, Blendis L. Pathophysiology of sodium retention and ascites formation in cirrhosis: role of atrial natriuretic factor. Semin Liver Dis. 1994 Feb;14(1):59–70. [PubMed]
  • Tomita K, Ujiie K, Nakanishi T, Tomura S, Matsuda O, Ando K, Shichiri M, Hirata Y, Marumo F. Plasma endothelin levels in patients with acute renal failure. N Engl J Med. 1989 Oct 19;321(16):1127–1127. [PubMed]
  • Forns X, Ginès A, Ginès P, Arroyo V. Management of ascites and renal failure in cirrhosis. Semin Liver Dis. 1994 Feb;14(1):82–96. [PubMed]
  • Laffi G, La Villa G, Gentilini P. Pathogenesis and management of the hepatorenal syndrome. Semin Liver Dis. 1994 Feb;14(1):71–81. [PubMed]
  • Fulenwider JT, Galambos JD, Smith RB, 3rd, Henderson JM, Warren WD. LeVeen vs Denver peritoneovenous shunts for intractable ascites of cirrhosis. A randomized, prospective trial. Arch Surg. 1986 Mar;121(3):351–355. [PubMed]
  • Titó L, Ginès P, Arroyo V, Planas R, Panés J, Rimola A, Llach J, Humbert P, Badalamenti S, Jiménez W, et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology. 1990 Jan;98(1):146–151. [PubMed]
  • Ginès P, Arroyo V, Vargas V, Planas R, Casafont F, Panés J, Hoyos M, Viladomiu L, Rimola A, Morillas R, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med. 1991 Sep 19;325(12):829–835. [PubMed]
  • Ring EJ, Lake JR, Roberts JP, Gordon RL, LaBerge JM, Read AE, Sterneck MR, Ascher NL. Using transjugular intrahepatic portosystemic shunts to control variceal bleeding before liver transplantation. Ann Intern Med. 1992 Feb 15;116(4):304–309. [PubMed]
  • Conn HO. Transjugular intrahepatic portal-systemic shunts: the state of the art. Hepatology. 1993 Jan;17(1):148–158. [PubMed]
  • Knechtle SJ, Kalayoglu M, D'Alessandro AM, Pirsch JD, Armbrust MJ, Sproat IA, Wojtowycz MM, McDermott JC, Crummy AB, Belzer FO. Portal hypertension: surgical management in the 1990s. Surgery. 1994 Oct;116(4):687–695. [PubMed]
  • Rimola A, Gavaler JS, Schade RR, el-Lankany S, Starzl TE, Van Thiel DH. Effects of renal impairment on liver transplantation. Gastroenterology. 1987 Jul;93(1):148–156. [PubMed]
  • Powell-Jackson PR, Young B, Calne RY, Williams R. Nephrotoxicity of parenterally administered cyclosporine after orthotopic liver transplantation. Transplantation. 1983 Nov;36(5):505–508. [PubMed]
  • Iwatsuki S, Esquivel CO, Klintmalm GB, Gordon RD, Shaw BW, Jr, Starzl TE. Nephrotoxicity of cyclosporine in liver transplantation. Transplant Proc. 1985 Aug;17(4 Suppl 1):191–195. [PMC free article] [PubMed]
  • Williams R, Blackburn A, Neuberger J, Calne RY. Long-term use of cyclosporin in liver grafting. Q J Med. 1985 Dec;57(224):897–905. [PubMed]
  • Ring-Larsen H, Palazzo U. Renal failure in fulminant hepatic failure and terminal cirrhosis: a comparison between incidence, types, and prognosis. Gut. 1981 Jul;22(7):585–591. [PMC free article] [PubMed]
  • Koppel MH, Coburn JW, Mims MM, Goldstein H, Boyle JD, Rubini ME. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome. Evidence for the functionalnature of renal failure in advanced liver disease. N Engl J Med. 1969 Jun 19;280(25):1367–1371. [PubMed]
  • Arroyo V, Ginés P. Prostaglandins and the treatment of hepatorenal syndrome in cirrhosis. J Hepatol. 1990 Sep;11(2):142–144. [PubMed]
  • Pérez-Ayuso RM, Arroyo V, Camps J, Rimola A, Costa J, Gaya J, Rivera F, Rodés J. Renal kallikrein excretion in cirrhotics with ascites: relationship to renal hemodynamics. Hepatology. 1984 Mar-Apr;4(2):247–252. [PubMed]
  • Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology. 1988 Mar-Apr;8(2):232–236. [PubMed]
  • Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation (2). N Engl J Med. 1989 Oct 19;321(16):1092–1099. [PubMed]
  • Iwatsuki S, Popovtzer MM, Corman JL, Ishikawa M, Putnam CW, Katz FH, Starzl TE. Recovery from "hepatorenal syndrome" after orthotopic liver transplantation. N Engl J Med. 1973 Nov 29;289(22):1155–1159. [PMC free article] [PubMed]
  • Iwatsuki S, Esquivel CO, Gordon RD, Shaw BW, Jr, Starzl TE, Shade RR, Van Thiel DH. Liver transplantation for fulminant hepatic failure. Semin Liver Dis. 1985 Nov;5(4):325–328. [PMC free article] [PubMed]
  • Wood RP, Ellis D, Starzl TE. The reversal of the hepatorenal syndrome in four pediatric patients following successful orthotopic liver transplantation. Ann Surg. 1987 Apr;205(4):415–419. [PMC free article] [PubMed]
  • Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome--experience in 300 patients. Transplantation. 1991 Feb;51(2):428–430. [PubMed]
  • Simpson KM, Bunch DL, Amemiya H, Boehmig HJ, Wilson CB, Dixon FJ, Coburg AJ, Hathaway WE, Giles GR, Starzl TE. Humoral antibodies and coagulation mechanisms in the accelerated or hyperacute rejection of renal homografts in sensitized canine recipients. Surgery. 1970 Jul;68(1):77–85. [PMC free article] [PubMed]
  • Margreiter R, Kramar R, Huber C, Steiner E, Niederwieser D, Judmaier G, Vogel W. Combined liver and kidney transplantation. Lancet. 1984 May 12;1(8385):1077–1078. [PubMed]
  • Gonwa TA, Nery JR, Husberg BS, Klintmalm GB. Simultaneous liver and renal transplantation in man. Transplantation. 1988 Nov;46(5):690–693. [PubMed]
  • Gonwa TA, Poplawski S, Paulsen W, Brajtbord D, Goldstein R, Husberg B, Klintmalm GB. Pathogenesis and outcome of hepatorenal syndrome in patients undergoing orthotopic liver transplant. Transplantation. 1989 Feb;47(2):395–397. [PubMed]
  • McDonald JC, Landreneau MD, Rohr MS, DeVault GA., Jr Reversal by liver transplantation of the complications of primary hyperoxaluria as well as the metabolic defect. N Engl J Med. 1989 Oct 19;321(16):1100–1103. [PubMed]
  • Scheinman JI. Primary hyperoxaluria: therapeutic strategies for the 90's. Kidney Int. 1991 Sep;40(3):389–399. [PubMed]
  • Watts RW, Calne RY, Williams R, Mansell MA, Veall N, Purkiss P, Rolles K. Primary hyperoxaluria (type I): attempted treatment by combined hepatic and renal transplantation. Q J Med. 1985 Oct;57(222):697–703. [PubMed]
  • Taylor JE, Calne RY, Stewart WK. Massive cystic hepatomegaly in a female patient with polycystic kidney disease treated by combined hepatic and renal transplantation. Q J Med. 1991 Sep;80(293):771–775. [PubMed]
  • Uribarri J, Miller C, Burrows L. Combined liver-kidney transplantation. For the genetic disorder primary hyperoxaluria type I. Mt Sinai J Med. 1994 Jan;61(1):32–36. [PubMed]
  • Starzl TE, Klintmalm GB, Porter KA, Iwatsuki S, Schröter GP. Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med. 1981 Jul 30;305(5):266–269. [PMC free article] [PubMed]
  • Venkataramanan R, Burckhart GJ, Ptachcinski RJ. Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation. Semin Liver Dis. 1985 Nov;5(4):357–368. [PubMed]
  • Cakaloglu Y, Devlin J, O'Grady J, Sutherland S, Portmann BC, Heaton N, Tan KC, Williams R. Importance of concomitant viral infection during late acute liver allograft rejection. Transplantation. 1995 Jan 15;59(1):40–45. [PubMed]
  • Sandborn WJ, Lawson GM, Cody TJ, Porayko MK, Hay JE, Gores GJ, Steers JL, Krom RA, Wiesner RH. Early cellular rejection after orthotopic liver transplantation correlates with low concentrations of FK506 in hepatic tissue. Hepatology. 1995 Jan;21(1):70–76. [PubMed]
  • Myers BD, Newton L, Boshkos C, Macoviak JA, Frist WH, Derby GC, Perlroth MG, Sibley RK. Chronic injury of human renal microvessels with low-dose cyclosporine therapy. Transplantation. 1988 Nov;46(5):694–703. [PubMed]
  • Kanazi G, Stowe N, Steinmuller D, Hwieh HH, Novick AC. Effect of cyclosporine upon the function of ischemically damaged kidneys in the rat. Transplantation. 1986 Jun;41(6):782–784. [PubMed]
  • Hamilton DV, Calne RY, Evans DB, Henderson RG, Thiru S, White DJ. The effect of long-term cyclosporin A on renal function. Lancet. 1981 May 30;1(8231):1218–1219. [PubMed]
  • Duarte R. Cyclosporine: renal effects and prostacyclin. Ann Intern Med. 1985 Mar;102(3):420–420. [PubMed]
  • Coffman TM, Carr DR, Yarger WE, Klotman PE. Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation. 1987 Feb;43(2):282–285. [PubMed]
  • Sandborn WJ, Hay JE, Porayko MK, Gores GJ, Steers JL, Krom RA, Wiesner RH. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology. 1994 Apr;19(4):925–932. [PubMed]
  • Jindal RM. Posttransplant diabetes mellitus--a review. Transplantation. 1994 Dec 27;58(12):1289–1298. [PubMed]
  • Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature. 1989 Oct 26;341(6244):755–757. [PubMed]
  • Todo S, Ueda Y, Demetris JA, Imventarza O, Nalesnik M, Venkataramanan R, Makowka L, Starzl TE. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery. 1988 Aug;104(2):239–249. [PMC free article] [PubMed]
  • Todo S, Fung JJ, Demetris AJ, Jain A, Venkataramanan R, Starzl TE. Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc. 1990 Feb;22(1):13–16. [PMC free article] [PubMed]
  • McCauley J, Fung JJ, Todo S, Jain A, Deballi P, Starzl TE. Changes in renal function after liver transplantation under FK 506. Transplant Proc. 1991 Dec;23(6):3143–3145. [PMC free article] [PubMed]
  • Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, Neuhaus P. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation. 1994 Jul 27;58(2):170–178. [PubMed]
  • Todo S, Fung JJ, Starzl TE, Tzakis A, Doyle H, Abu-Elmagd K, Jain A, Selby R, Bronsther O, Marsh W, et al. Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg. 1994 Sep;220(3):297–309. [PMC free article] [PubMed]
  • Jindal RM, Popescu I, Emre S, Schwartz ME, Boccagni P, Meneses P, Mor E, Sheiner P, Miller CM. Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. Transplantation. 1994 May 15;57(9):1395–1398. [PubMed]
  • Neuhaus P, Blumhardt G, Bechstein WO, Platz KP, Jonas S, Mueller AR, Langrehr JM, Lohmann R, Schattenfroh N, Knoop M, et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. Transplantation. 1995 Jan 15;59(1):31–40. [PubMed]
  • Demetris AJ, Fung JJ, Todo S, McCauley J, Jain A, Takaya S, Alessiani M, Abu-Elmagd K, Van Thiel DH, Starzl TE. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. Transplantation. 1992 May;53(5):1056–1062. [PMC free article] [PubMed]
  • Ochiai T, Hamaguchi K, Isono K. Histopathologic studies in renal transplant recipient dogs receiving treatment with FK-506. Transplant Proc. 1987 Oct;19(5 Suppl 6):93–97. [PubMed]
  • Stephen M, Woo J, Hasan NU, Whiting PH, Thomson AW. Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. Transplantation. 1989 Jan;47(1):60–65. [PubMed]
  • Moutabarrik A, Ishibashi M, Fukunaga M, Kameoka H, Kawaguchi N, Takano Y, Kokado Y, Sonoda T, Onishi S, Takahara S, et al. FK506-induced kidney tubular cell injury. Transplantation. 1992 Dec;54(6):1041–1047. [PubMed]
  • Benigni A, Morigi M, Perico N, Zoja C, Amuchastegui CS, Piccinelli A, Donadelli R, Remuzzi G. The acute effect of FK506 and cyclosporine on endothelial cell function and renal vascular resistance. Transplantation. 1992 Nov;54(5):775–780. [PubMed]
  • Textor SC, Wiesner R, Wilson DJ, Porayko M, Romero JC, Burnett JC, Jr, Gores G, Hay E, Dickson ER, Krom RA. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation. 1993 Jun;55(6):1332–1339. [PubMed]
  • Millis JM, McDiarmid SV, Hiatt JR, Brems JJ, Colonna JO, 2nd, Klein AS, Ashizawa T, Hart J, Lewin K, Goldstein LI, et al. Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation. Transplantation. 1989 Jan;47(1):82–88. [PubMed]
  • Millis JM, Baquerizo A, Saleh S, Danovitch GM, Busuttil RW. Preservation of renal function using OKT3 in liver transplant patients. Transplant Proc. 1989 Jun;21(3):3551–3552. [PubMed]
  • Houghton S, Frei JV, Ghent CN. Use of OKT3 in liver transplant patients. Transplantation. 1989 Dec;48(6):1079–1079. [PubMed]
  • Hamilton G, Mühlbacher F, Steininger R, Havel M, Kreuzer S, Laengle F, Piza F. Lymphocyte parameters in liver graft recipients receiving prophylactic OKT3 or conventional triple therapy. Transplant Proc. 1989 Feb;21(1 Pt 2):2255–2256. [PubMed]
  • First MR, Schroeder TJ, Hurtubise PE, Mansour ME, Penn I, Munda R, Balistreri WF, Alexander JW, Melvin DB, Fidler JP, et al. Successful retreatment of allograft rejection with OKT3. Transplantation. 1989 Jan;47(1):88–91. [PubMed]
  • McDiarmid SV, Millis M, Terashita G, Ament ME, Busuttil R, Terasaki P. Low serum OKT3 levels correlate with failure to prevent rejection in orthotopic liver transplant patients. Transplant Proc. 1990 Aug;22(4):1774–1776. [PubMed]
  • McDiarmid SV, Millis MJ, Terasaki PI, Ament ME, Busuttil RW. OKT3 prophylaxis in liver transplantation. Dig Dis Sci. 1991 Oct;36(10):1418–1426. [PubMed]
  • Renard TH, Andrews WS, Foster ME. Relationship between OKT3 administration, EBV seroconversion, and the lymphoproliferative syndrome in pediatric liver transplant recipients. Transplant Proc. 1991 Feb;23(1 Pt 2):1473–1476. [PubMed]
  • Jindal RM, Tepper MA, Soltys K, Cho SI. Deoxyspergualin--a novel immunosuppressant. Mt Sinai J Med. 1994 Jan;61(1):51–56. [PubMed]
  • Platz KP, Eckhoff DE, Hullett DA, Sollinger HW. RS-61443 studies: review and proposal. Transplant Proc. 1991 Apr;23(2 Suppl 2):33–35. [PubMed]
  • Toto RD. The role of prostaglandins in NSAID induced renal dysfunction. J Rheumatol Suppl. 1991 Mar;28:22–25. [PubMed]
  • Pomer S, Röhl L, Hull W, Behringer J, Schmidt-Gayk H. Reduction of cyclosporine nephrotoxicity by prostaglandin E2 after experimental renal transplantation. Transplant Proc. 1987 Oct;19(5):4041–4042. [PubMed]
  • Grazi GL, Mazziotti A, Sama C, Stefanini GF, Gozzetti G. Reversal of primary liver graft non-function using prostaglandins. Hepatogastroenterology. 1991 Jun;38(3):254–256. [PubMed]
  • Miyazaki M, Makowka L, Falk RE, Falk JA, McDonell M, Venturi D. Protection of thermochemotherapeutic-induced lethal acute hepatic necrosis in the rat by 16,16-dimethyl prostaglandin E2. J Surg Res. 1983 May;34(5):415–426. [PubMed]
  • Sinclair SB, Greig PD, Blendis LM, Abecassis M, Roberts EA, Phillips MJ, Cameron R, Levy GA. Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report. J Clin Invest. 1989 Oct;84(4):1063–1069. [PMC free article] [PubMed]
  • Kaufman RP, Jr, Anner H, Kobzik L, Valeri CR, Shepro D, Hechtman HB. Vasodilator prostaglandins (PG) prevent renal damage after ischemia. Ann Surg. 1987 Feb;205(2):195–198. [PMC free article] [PubMed]
  • Greig PD, Woolf GM, Sinclair SB, Abecassis M, Strasberg SM, Taylor BR, Blendis LM, Superina RA, Glynn MF, Langer B, et al. Treatment of primary liver graft nonfunction with prostaglandin E1. Transplantation. 1989 Sep;48(3):447–453. [PubMed]
  • Moran M, Mozes MF, Maddux MS, Veremis S, Bartkus C, Ketel B, Pollak R, Wallemark C, Jonasson O. Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. N Engl J Med. 1990 Apr 26;322(17):1183–1188. [PubMed]
  • Adams MB. Enisoprost in renal transplantation. The Enisoprost Renal Transplant Study Group. Transplantation. 1992 Feb;53(2):338–345. [PubMed]
  • McCauley J, Gaynord M, Hrinya M, Starzl TE. Dialysis in liver failure and liver transplantation. Transplant Proc. 1993 Apr;25(2):1740–1740. [PMC free article] [PubMed]
  • Opolon P, Rapin JR, Huguet C, Granger A, Delorme ML, Boschat M, Sausse A. Hepatic failure coma (HFC) treated by polyacrylonitrile membrane (PAN) hemodialysis (HD). Trans Am Soc Artif Intern Organs. 1976;22:701–710. [PubMed]
  • Hakim RM, Wingard RL, Parker RA. Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med. 1994 Nov 17;331(20):1338–1342. [PubMed]
  • Schiffl H, Lang SM, König A, Strasser T, Haider MC, Held E. Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet. 1994 Aug 27;344(8922):570–572. [PubMed]
  • Rozga J, Podesta L, LePage E, Morsiani E, Moscioni AD, Hoffman A, Sher L, Villamil F, Woolf G, McGrath M, et al. A bioartificial liver to treat severe acute liver failure. Ann Surg. 1994 May;219(5):538–546. [PMC free article] [PubMed]
  • Chari RS, Collins BH, Magee JC, DiMaio JM, Kirk AD, Harland RC, McCann RL, Platt JL, Meyers WC. Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation. N Engl J Med. 1994 Jul 28;331(4):234–237. [PubMed]
  • Rozga J, Podesta L, LePage E, Hoffman A, Morsiani E, Sher L, Woolf GM, Makowka L, Demetriou AA. Control of cerebral oedema by total hepatectomy and extracorporeal liver support in fulminant hepatic failure. Lancet. 1993 Oct 9;342(8876):898–899. [PubMed]
  • Starzl TE, Fung J, Tzakis A, Todo S, Demetris AJ, Marino IR, Doyle H, Zeevi A, Warty V, Michaels M, et al. Baboon-to-human liver transplantation. Lancet. 1993 Jan 9;341(8837):65–71. [PMC free article] [PubMed]
  • Sheiner PA, Schwartz ME, Mor E, Schluger LK, Theise N, Kishikawa K, Kolesnikov V, Bodenheimer H, Emre S, Miller CM. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology. 1995 Jan;21(1):30–34. [PubMed]
  • Misiani R, Bellavita P, Fenili D, Borelli G, Marchesi D, Massazza M, Vendramin G, Comotti B, Tanzi E, Scudeller G, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med. 1992 Oct 1;117(7):573–577. [PubMed]
  • Misiani R, Bellavita P, Fenili D. Hepatitis C virus and cryoglobulinemia. N Engl J Med. 1993 Apr 15;328(15):1121–1124. [PubMed]
  • Cacoub P, Lunel F, Musset L, Opolon P, Piette JC. Hepatitis C virus and cryoglobulinemia. N Engl J Med. 1993 Apr 15;328(15):1121–1124. [PubMed]
  • Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med. 1992 Nov 19;327(21):1490–1495. [PubMed]
  • Werner C, Joller-Jemelka HI, Fontana A. Hepatitis C virus and cryoglobulinemia. N Engl J Med. 1993 Apr 15;328(15):1122–1124. [PubMed]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...